PTC Therapeutics announced the initiation of a Phase 2 clinical trial to test the safety, tolerability, and efficacy of the small molecule RG7916 for the treatment of children and adults with type 2 and type 3 spinal muscular atrophy (SMA).
PTC Therapeutics announced the initiation of a Phase 2 clinical trial to test the safety, tolerability, and efficacy of the small molecule RG7916 for the treatment of children and adults with type 2 and type 3 spinal muscular atrophy (SMA).
In this touching video from FightSMA, we meet the Kemp family. Having already suffered the sadness of losing their daughter Madisyn to Type 1 spinal muscular atrophy (SMA) in 2008, Brandon and Patti went on to have three more children. Find out what the three main symptoms of…
In this video from BettyLou Ross, we meet some families with a child that has spinal muscular atrophy (SMA). The families talk about living with SMA and their hopes for the future, like being able to live independently, have a career, and ultimately see a cure which would…
Spinraza (nusinersen) for spinal muscular atrophy (SMA) met the primary endpoint in an interim analysis from a Phase 3 clinical trial evaluating the treatment in children with later-onset (consistent with Type 2) SMA. Biogen and Ionis Pharmaceuticals reported that children treated with Spinraza had a highly statistically significant improvement in motor…
AveXis reported that the planned pivotal clinical trial of its gene therapy candidate AVXS-101 for spinal muscular atrophy (SMA) Type 1 will enroll about 20 patients and will have a single-arm design, with the comparator being the natural disease history. This update follows the Type B meeting Sept. 30 with the…
Get regular updates to your inbox.